Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Jean Roy, MD, Tony Panzarella, M.Sc., P.Stat, Stephen Couban, MDBSc, Félix Couture, MD FRCPC, Gerald M. Devins, PhD, Mohamed Elemary, MD, Stephen Ronan Foley, MD FRCPC, Genevieve Gallagher, MD, John Kuruvilla, MD, Stephanie J. Lee, MD MPH, John Moore, MDFRACP,FRCPA, Thomas J Nevill, MD, Gizelle Popradi, MD FRCP, Kirk R. Schultz, MD, David Szwajcer, MD FRCPC, Cynthia L Toze, MD FRCPC, Irwin Walker, MBBS, FRCPC

Blood (2019) 134 (Supplement_1): 875.

https://doi.org/10.1182/blood-2019-123275

Published: 2019

Journal Articles

Provincial Disparities in Access to Allogeneic Transplant in Canada

Kristjan Paulson, MD, Oliver Bucher, Geoffrey Cuvelier, MD, Andrew Daly, MD, Alina S. Gerrie, MD MPH, David Sanford, MD, David Szwajcer, MD FRCP(C), Matthew Seftel, MRCP, MD MPH, FRCPC, Irwin Walker, MBBS, Natasha Kekre, MD FRCPC, Tony H Truong, MD FRCPC, Donna Wall, MD CCPE, Kirk R. Schultz, MD, Stephen Couban, MDBSc, Christopher Bredeson, MD FRCPC, MSc

Blood (2018) 132 (Supplement 1): 4742.

https://doi.org/10.1182/blood-2018-99-113849

Published: 2018

Journal Articles

Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A CIBMTR Analysis

Kristjan Paulson, MD, Ruta Brazauskas, PhD, Naya He, MPH, David Szwajcer, MD, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Yoshiko Atsuta, MD PhD, Jignesh D Dalal, MD, Theresa Hahn, PhD, Carmem Bonfim, MD, Nandita Khera, MD, Linda J. Burns, MD, Lih-Wen Mau, PhD MPH, Navneet S. Majhail, MD, Wael Saber, MD MS

Blood (2016) 128 (22): 842.

https://doi.org/10.1182/blood.V128.22.842.842

Published: 2016

Journal Articles

Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial

Blood (2014) 124 (21): 209.

https://doi.org/10.1182/blood.V124.21.209.209

Published: 2014

Journal Articles

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Tara Baetz, MD, Bingshu E Chen, PhD, Stephen Couban, MD, C. Tom Kouroukis, MD MSc, FRCPC, Rena Buckstein, MD, John Kuruvilla, MD, Kang Howson-Jan, David Szwajcer, MD FRCPC, Massimo Federico, MD, Ralph M. Meyer, Robert Turner, MD, Marina S Djurfeldt, MSc, Annette E Hay, MB ChB, Lois Shepherd, MD, Michael Crump, MD

Blood (2014) 124 (21): 1712.

https://doi.org/10.1182/blood.V124.21.1712.1712

Published: 2014

Journal Articles

Plerixafor Successfully Rescues Poor Mobilizers Resulting in Adequate CD34 Cell Numbers However Stem Cell Products Yield Lower Numbers of CFU/CD34 and Delayed Neutrophil Engraftment

David Szwajcer, MD FRCPC, Anna Blankstein, Miranda M. Charette, MD, Qingdong Guan, MD PhD, Donna A. Wall, MD

Blood (2014) 124 (21): 2450.

https://doi.org/10.1182/blood.V124.21.2450.2450

Published: 2014

Journal Articles

Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial

Irwin Walker, MBBS, Kirk R. Schultz, MD, Cynthia L. Toze, MD FRCPC, Holly Margaret Kerr, RN, BSN, John Moore, MD, David Szwajcer, MD FRCPC, Stephen Ronan Foley, MD FRCPC, John Kuruvilla, MD FRCPC, Tony Panzarella, M.Sc, Félix Couture, MD, Jean Roy, MD, Stephen Couban, MD FRCPC, Gerald Devins, PhD, Gizelle Popradi, FRCPC, MD, Stephanie J. Lee, MD MPH, Jason Tay, MD MSc, FRCPC, Thomas J. Nevill, MD FRCPC, Mohamed Elemary, MD MSc,PhD, Genevieve Gallagher, MD FRCPC

Blood (2014) 124 (21): 38.

https://doi.org/10.1182/blood.V124.21.38.38

Published: 2014

Journal Articles

Low CD34 Cell Dose Is Associated With Higher Non-Relapse and Overall Mortality After Reduced Intensity Conditioning Hematopoietic Cell Transplantation For Acute Myeloid Leukemia and Myelodysplastic Syndrome

Johan Thörlén, MD, Olle Ringdén, MD, PhD, Jennifer Le Rademacher, PhD, Minoo Battiwalla, MD, MS, Junfang Chen, MS, Vincent T. Ho, MD, Partow Kebriaei, MD, Carolyn A. Keever-Taylor, PhD, Tamila L. Kindwall-Keller, DO, Hillard M. Lazarus, MD, Mary J. Laughlin, MD, Michael Lill, MD, BS, Tracey A. O’Brien, FRACP, MBChB, MHL, BSc, Miguel Angel Perales, MD, Vanderson Rocha, MD, PhD, Bipin N. Savani, MD, David Szwajcer, MD, FRCPC, David Valcarcel, MD, Mary Eapen, MBBS, MS

Blood (2013) 122 (21): 3342.

https://doi.org/10.1182/blood.V122.21.3342.3342

Published: 2013

Journal Articles

Survival Improvements Following Myeloablative Allogeneic Hematopoietic Cell Transplantation For Acute Lymphoblastic Leukemia In Adolescents and Young Adults Have Been Comparable To Younger Children: A Study From The Cibmtr

William A. Wood, MD, MPH, Stephanie J. Lee, MD, MPH, Ruta Brazauskas, PhD, Zhiwei Wang, MS, Mahmoud D. Aljurf, MD, Karen K. Ballen, MD, David K. Buchbinder, MD, MSHS, Jason Dehn, MPH, CHTC, César O Freytes, MD, Hillard M. Lazarus, MD, Charles F. LeMaistre, MD, Paulette Mehta, MD, MPH, David Szwajcer, MD, FRCPC, Steven Joffe, MD, MPH, Navneet S. Majhail, MD, MS

Blood (2013) 122 (21): 554.

https://doi.org/10.1182/blood.V122.21.554.554

Published: 2013

Journal Articles

A Canadian Blood and Marrow Transplant Group (CBMTG) Randomised Trial Comparing G-CSF Mobilized Peripheral Blood Versus G-CSF Stimulated Bone Marrow In Recipients Of Sibling Allografts For Hematologic Malignancies

Blood (2013) 122 (21): 709.

https://doi.org/10.1182/blood.V122.21.709.709

Published: 2013

Journal Articles

The Valproic Acid-Fludarabine Combination Induces a Synergistic Response in Chronic Lymphocytic Leukemia Via a Mechanism Involving the Lysosomal Protease Cathepsin B.

Ju-Yoon Yoon, David Szwajcer, MD, FRCPC, Ganchimeg Ishdorj, PhD, Pat Benjaminson, RN, CON(C), James B Johnston, MD, Spencer B Gibson, PhD

Blood (2012) 120 (21): 2892.

https://doi.org/10.1182/blood.V120.21.2892.2892

Published: 2012

Journal Articles

Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,

Donna E. Reece, MD, FRCPC, Giovanni Piza Rodriguez, MD, David Szwajcer, MD, FRCPC, Leonard A Minuk, MD, FRCPC, Mariela Pantoja, MSc, PhD, Andrew Belch, MD, Chaim Shustik, MD, Julie Stakiw, MD, Darrell J. White, MD, Christine Chen, MD, MSC, FRCPC, Vishal Kukreti, MD, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Michael Sebag, MD, PhD, Gayle Jenkins, Nizar J Bahlis, MD, Lisa W Le, MSc, Suzanne Trudel, MD

Blood (2011) 118 (21): 3982.

https://doi.org/10.1182/blood.V118.21.3982.3982

Published: 2011

Journal Articles

Prospective Canadian Trial In Newly Diagnosed Multiple Myeloma Patients with t(4;14): Bortezomib-Based Therapy without ASCT

Donna E. Reece, MD, Giovanni Piza Rodriguez, Andrew Belch, MD, David Szwajcer, MD, FRCP(C), Michael J. Kovacs, MD, FRCPC, Chaim Shustik, MD, Nizar J Bahlis, MD, Darrell J White, MD, Mariela Pantoja, Christine Chen, MD, Vishal Kukreti, MD, FRCPC, Peter Anglin, MD, Suzanne Trudel, MD, MSC, FRCPC

Blood (2010) 116 (21): 1968.

https://doi.org/10.1182/blood.V116.21.1968.1968

Published: 2010

Journal Articles

Incidence and Clinical Features of Acute Promyelocytic Leukemia In a Population-Based Canadian Cohort

Kristjan Paulson, MD, FRCPC, David Szwajcer, MD, FRCP(C), Arshad Ahsanuddin, MD, Pascal Lambert, MSc, Donna Turner, Ph.D., Morel Rubinger, MD, FRCPC, Rajat Kumar, FRCPC, Matthew D. Seftel, MRCP, FRCPC, MPH

Blood (2010) 116 (21): 4374.

https://doi.org/10.1182/blood.V116.21.4374.4374

Published: 2010

Journal Articles

Effect of Valproic Acid (VPA) on Fludarabine Activity In Chronic Lymphocytic Leukemia (CLL) Patients

Ju-Yoon Yoon, MSc, HonBSc, David Szwajcer, MD, FRCP(C), Ganchimeg Ishdorj, PhD, Pat Benjaminson, RN, CON(C), Spencer B Gibson, PhD, James B Johnston, MD, FRCPC

Blood (2010) 116 (21): 4626.

https://doi.org/10.1182/blood.V116.21.4626.4626

Published: 2010

Journal Articles

The Population Based Incidence of Myelodysplastic Syndrome (MDS): Utility of Multiple Data Sources and Follow-up.

Rajat Kumar, FRCPC, Charles Musuka, FRCPath, FRCPC, Humaira Khair, Matthew D. Seftel, MBChB, FRCP(C), MRCP, David Szwajcer, MD, FRCPC, Cheryl Clague, Gail Noonan, Alain Demers, PhD

Blood (2009) 114 (22): 245.

https://doi.org/10.1182/blood.V114.22.245.245

Published: 2009

Journal Articles

Bortezomib-Based Therapy, without Stem Cell Transplantation, for Newly Diagnosed Multiple Myeloma Patients with t(4;14).

Donna E. Reece, MD, Giovanni Piza Rodriguez, Andrew Belch, MD, David Szwajcer, MD, Mariela Pantoja, Michael Kovacs, MD, Chaim Shustik, MD, Nizar J Bahlis, MD, Darrell J White, MD, Christine Chen, MD, Vishal Kukreti, MD, FRCPC, Peter Anglin, MD, A. Keith Stewart, MD, Suzanne Trudel

Blood (2009) 114 (22): 3861.

https://doi.org/10.1182/blood.V114.22.3861.3861

Published: 2009

Journal Articles

Modest Prolongation of Survival for Patients 60-80 Year at Time of Acute Myelogenous Leukemia (AML) Diagnosis Who Are Treated with Conventional AML Therapy: A Provincial Cohort Analysis.

Maneesh Sud, BSc, Demers Alain, PhD, Rajat Kumar, FRCP, Grace Musto, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Erin Richardson, Morel Rubinger, MD, FRCPC, Brent Allan Schacter, MD, Donna A. Wall, MD, David Szwajcer, MD

Blood (2009) 114 (22): 4125.

https://doi.org/10.1182/blood.V114.22.4125.4125

Published: 2009

Journal Articles

Oral Warfarin Remains An Effective Treatment Option in the Extended Prophylaxis of VTE for Patients with Cancer: The Effectiveness of the CancerCare Manitoba (CCMB) Anticoagulation Clinic (ACC).

Vi Dao, MD, David Szwajcer, MD, Rick Prayag, PharmD, Don Houston, MD, PhD

Blood (2008) 112 (11): 1283.

https://doi.org/10.1182/blood.V112.11.1283.1283

Published: 2008

Journal Articles

Does Location Matter? a Population-Based Analysis of Survival after Blood and Marrow Transplantation in Rural Versus Urban Manitobans

Kristjan Paulson, MD, Pascal Lambert, MSc, David Szwajcer, MD, FRCP(C), Janet Nowatzki, Christopher Bredeson, MD, MSc, FRCP(C), Erin Richardson, Morel Rubinger, MD, FRCPC, Matthew D. Seftel, MBChB, FRCP(C), MRCP

Blood (2008) 112 (11): 2365.

https://doi.org/10.1182/blood.V112.11.2365.2365

Published: 2008

NARROW

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Provincial Disparities in Access to Allogeneic Transplant in Canada

Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A CIBMTR Analysis

Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Plerixafor Successfully Rescues Poor Mobilizers Resulting in Adequate CD34 Cell Numbers However Stem Cell Products Yield Lower Numbers of CFU/CD34 and Delayed Neutrophil Engraftment

Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial

Low CD34 Cell Dose Is Associated With Higher Non-Relapse and Overall Mortality After Reduced Intensity Conditioning Hematopoietic Cell Transplantation For Acute Myeloid Leukemia and Myelodysplastic Syndrome

Survival Improvements Following Myeloablative Allogeneic Hematopoietic Cell Transplantation For Acute Lymphoblastic Leukemia In Adolescents and Young Adults Have Been Comparable To Younger Children: A Study From The Cibmtr

A Canadian Blood and Marrow Transplant Group (CBMTG) Randomised Trial Comparing G-CSF Mobilized Peripheral Blood Versus G-CSF Stimulated Bone Marrow In Recipients Of Sibling Allografts For Hematologic Malignancies

The Valproic Acid-Fludarabine Combination Induces a Synergistic Response in Chronic Lymphocytic Leukemia Via a Mechanism Involving the Lysosomal Protease Cathepsin B.

Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,

Prospective Canadian Trial In Newly Diagnosed Multiple Myeloma Patients with t(4;14): Bortezomib-Based Therapy without ASCT

Incidence and Clinical Features of Acute Promyelocytic Leukemia In a Population-Based Canadian Cohort

Effect of Valproic Acid (VPA) on Fludarabine Activity In Chronic Lymphocytic Leukemia (CLL) Patients

The Population Based Incidence of Myelodysplastic Syndrome (MDS): Utility of Multiple Data Sources and Follow-up.

Bortezomib-Based Therapy, without Stem Cell Transplantation, for Newly Diagnosed Multiple Myeloma Patients with t(4;14).

Modest Prolongation of Survival for Patients 60-80 Year at Time of Acute Myelogenous Leukemia (AML) Diagnosis Who Are Treated with Conventional AML Therapy: A Provincial Cohort Analysis.

Oral Warfarin Remains An Effective Treatment Option in the Extended Prophylaxis of VTE for Patients with Cancer: The Effectiveness of the CancerCare Manitoba (CCMB) Anticoagulation Clinic (ACC).

Does Location Matter? a Population-Based Analysis of Survival after Blood and Marrow Transplantation in Rural Versus Urban Manitobans

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only